[
  {
    "ts": null,
    "headline": "Wells Fargo Initiates Coverage of ResMed (RMD) with Equal-Weight Recommendation",
    "summary": "Wells Fargo Initiates Coverage of ResMed (RMD) with Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=035b3e56b76f835632b78aa99843926ea055c0222ac27ee60d24fbb237958380",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760392385,
      "headline": "Wells Fargo Initiates Coverage of ResMed (RMD) with Equal-Weight Recommendation",
      "id": 137071610,
      "image": "",
      "related": "RMD",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=035b3e56b76f835632b78aa99843926ea055c0222ac27ee60d24fbb237958380"
    }
  },
  {
    "ts": null,
    "headline": "BD Stock Down Despite Making Progress in the Treatment of PAD Lesions",
    "summary": "BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.",
    "url": "https://finnhub.io/api/news?id=5fff891ba921e916bc505fc00cd6b99693ce1ebaec1b195b8418fb9c117d8cc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760375640,
      "headline": "BD Stock Down Despite Making Progress in the Treatment of PAD Lesions",
      "id": 137068894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.",
      "url": "https://finnhub.io/api/news?id=5fff891ba921e916bc505fc00cd6b99693ce1ebaec1b195b8418fb9c117d8cc0"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Heavy Stocks to Research Further and 1 We Turn Down",
    "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
    "url": "https://finnhub.io/api/news?id=54931a4b7dff52e14d6788127f55c1c5b0e717fb10ec828049ef7349a5c36b90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760374915,
      "headline": "2 Cash-Heavy Stocks to Research Further and 1 We Turn Down",
      "id": 137068496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
      "url": "https://finnhub.io/api/news?id=54931a4b7dff52e14d6788127f55c1c5b0e717fb10ec828049ef7349a5c36b90"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Brush Off",
    "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
    "url": "https://finnhub.io/api/news?id=98ed187921cf71563ee77261616c659f28361b5921a729d4c3d3ba32157a3ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760351841,
      "headline": "2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Brush Off",
      "id": 137066246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
      "url": "https://finnhub.io/api/news?id=98ed187921cf71563ee77261616c659f28361b5921a729d4c3d3ba32157a3ff8"
    }
  },
  {
    "ts": null,
    "headline": "Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo",
    "summary": "Amid market uncertainty, low-leverage stocks RMD, SAFRY, PNR, CASY, and DRS emerge as safer investment options for steady growth.",
    "url": "https://finnhub.io/api/news?id=74f9e8fcff75f6dae4113b0e080b96a7e01a11e18580a3410a53a6e160a2c3f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760348820,
      "headline": "Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo",
      "id": 137066519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Amid market uncertainty, low-leverage stocks RMD, SAFRY, PNR, CASY, and DRS emerge as safer investment options for steady growth.",
      "url": "https://finnhub.io/api/news?id=74f9e8fcff75f6dae4113b0e080b96a7e01a11e18580a3410a53a6e160a2c3f1"
    }
  },
  {
    "ts": null,
    "headline": "Fractus files patent infringement complaint against ResMed in the Southern District of California",
    "summary": "Fractus, a pioneer in geometry-based antenna technology and IP licensing, today announced that it has filed a patent infringement complaint (3:25-cv-02680-LL-JLB) against ResMed in the United States District Court for the Southern District of California. The complaint alleges that ResMed's sleep apnea devices and related connected therapy solutions infringe multiple Fractus patents covering miniaturized, high-performance multi-band antenna innovations.",
    "url": "https://finnhub.io/api/news?id=59ba766b42381f9a2f6d4b830f3882caf916e24b5b9a29be9a78bf1a8187ddd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760342400,
      "headline": "Fractus files patent infringement complaint against ResMed in the Southern District of California",
      "id": 137066520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Fractus, a pioneer in geometry-based antenna technology and IP licensing, today announced that it has filed a patent infringement complaint (3:25-cv-02680-LL-JLB) against ResMed in the United States District Court for the Southern District of California. The complaint alleges that ResMed's sleep apnea devices and related connected therapy solutions infringe multiple Fractus patents covering miniaturized, high-performance multi-band antenna innovations.",
      "url": "https://finnhub.io/api/news?id=59ba766b42381f9a2f6d4b830f3882caf916e24b5b9a29be9a78bf1a8187ddd3"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (RMD): Exploring Valuation After Recent Share Price Pullback",
    "summary": "ResMed (RMD) shares have been edging slightly lower over the past week, giving investors a nudge to re-examine the company’s current position and longer-term potential. This move comes against a backdrop of steady year-to-date gains. See our latest analysis for ResMed. Momentum was clearly on ResMed’s side for much of the year, with its share price up 19.05% since January and delivering a 14.08% total shareholder return over the past twelve months. That recent pullback suggests some investors...",
    "url": "https://finnhub.io/api/news?id=db86960d6b3160150e70f4851d222b24f3f4f45f026e6e940dbb4ddc61bd9588",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760324763,
      "headline": "ResMed (RMD): Exploring Valuation After Recent Share Price Pullback",
      "id": 137063845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "ResMed (RMD) shares have been edging slightly lower over the past week, giving investors a nudge to re-examine the company’s current position and longer-term potential. This move comes against a backdrop of steady year-to-date gains. See our latest analysis for ResMed. Momentum was clearly on ResMed’s side for much of the year, with its share price up 19.05% since January and delivering a 14.08% total shareholder return over the past twelve months. That recent pullback suggests some investors...",
      "url": "https://finnhub.io/api/news?id=db86960d6b3160150e70f4851d222b24f3f4f45f026e6e940dbb4ddc61bd9588"
    }
  }
]